Cirrhosis
Livdelzi reduces cholestatic, liver injury markers in patients with PBC and cirrhosis
SAN DIEGO — Livdelzi appeared safe and well-tolerated and reduced markers of cholestasis and liver injury in patients with primary biliary cholangitis, including those with compensated cirrhosis, according to a presenter.
Mean arterial pressure target of 75 mmHg may boost survival in cirrhosis with septic shock
SAN DIEGO — Increasing the mean arterial pressure target to 75 mmHg lowered the odds of 28-day mortality by 85%, and also reduced the odds of acute kidney injury nonrecovery, in decompensated cirrhosis with septic shock, according to data.
VIDEO: ‘Encouraging’ safety data on Livdelzi in primary biliary cholangitis, cirrhosis
PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual Scientific Meeting investigating the use of Livdelzi in patients with primary biliary cholangitis and cirrhosis.
FDA denies Ocaliva full approval in primary biliary cholangitis; safety data still in play
The FDA issued a complete response letter to Intercept Pharmaceuticals indicating it cannot grant full approval to the company’s supplemental new drug application for Ocaliva as a treatment for primary biliary cholangitis.
VIDEO: ‘We should be exploring’ sodium-glucose inhibitors in cirrhosis treatment
PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, highlights a presentation evaluating the use of sodium-glucose cotransporter 2 inhibitors in patients with cirrhosis.
Patients with cirrhosis have higher risk for bleeding after endoscopic mucosal resection
PHILADELPHIA — Patients with cirrhosis had an increased risk for bleeding within 30 days of colorectal endoscopic mucosal resection compared with controls, although the need for reintervention or ICU admission was similar between groups.
‘Do your due diligence’ in cases of suspected, recurrent hepatic encephalopathy
PHILADELPHIA — Hepatologists and gastroenterologists must be internal medicine physicians, not just specialists, to determine the root cause of complaints in patients with suspected hepatic encephalopathy, according to an expert.
Rifaximin reduces risk for overt hepatic encephalopathy recurrence by 60% vs. lactulose
PHILADELPHIA — Rifaximin monotherapy reduced episode recurrence and “may confer” a survival benefit compared with lactulose monotherapy among patients with cirrhosis and a history of overt hepatic encephalopathy, according to a presenter.
‘Lack of quality evidence’ to support prolonged vasoconstrictor use for variceal bleeding
PHILADELPHIA — Use of vasoconstrictors for up to 120 hours following endoscopic variceal ligation for acute variceal bleeding failed to demonstrate additional benefits vs. early discontinuation, according to data.
Speech pattern analysis may help diagnose, predict ‘more subtle’ hepatic encephalopathy
A diagnostic tool based on speech variables helped identify minimal hepatic encephalopathy and may predict time to development of overt hepatic encephalopathy in patients with cirrhosis, according to a study published in Hepatology.